<DOC>
	<DOCNO>NCT02235727</DOCNO>
	<brief_summary>A Single Dose Study GBR 900 Healthy Volunteers .</brief_summary>
	<brief_title>Safety Tolerability GBR 900 Single Ascending Dose Study Healthy Subjects</brief_title>
	<detailed_description>This phase I study GBR 900 healthy volunteer . The purpose study look safety , well study drug tolerate , much study drug get blood stream , long take body get rid give human . Information side effect may occur also collect . Each participant remain study approximately 3.5 month . This study research purpose intend treat medical condition .</detailed_description>
	<criteria>1 . Body mass index ( BMI ) within range 18.532 kg/m2 ( inclusive ) ; weight must â‰¥ 50 kg . 2 . Men woman age 18 55 year ( inclusive ) . Female subject must nonchildbearing potential 3 . Subjects otherwise healthy free clinically significant illness disease determine medical history , vital sign , physical examination , test perform investigator . 1 . Subjects history neuropathy otherwise present risk factor neurological toxicity like chronic alcoholism clinically significant neurological ( e.g . dementia , cognitive decline , seizure disorder ) psychiatric disorder . 2 . Subjects recent history live vaccination within past 3 month presence active infection within previous month . 3 . Subjects previous exposure antibody therapies administration immunoglobulin ( Ig ) within 6 month randomization . 4 . Subjects history presence inflammatory disease rheumatological disease joint disease include OA undiagnosed pain joint . 5 . Subjects current and/or recent history arthralgia history fibromyalgia , migraine , neuralgia , systemic painful condition , medical arthritic condition undiagnosed pain systemic inflammatory disorder . 6 . Any evidence organ dysfunction clinically significant deviation normal history , physical neurological determination investigation clinical condition receive therapy , opinion Investigator , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>